A team of Duke pathologists led by Carolyn Glass, MD, PhD, has been awarded a $1.3 million grant from the National Institutes of Health to conduct the first in-depth study of long COVID’s effect at the tissue level.

By analyzing their spike proteins, Duke researchers reveal how the Omicron XBB variants balance stability, receptor usage and immune evasion.

Anthony S. Fauci, MD, visited Duke at the invitation of Bart Haynes, MD, Frederic M. Hanes Distinguished Professor of Medicine and director of the Duke Human Vaccine Institute (DHVI). He took the audience on a journey though time spanning his 58-year medical career.

The unique circumstances arising from the COVID-19 pandemic altered a long-held convention that doctors provide care regardless of personal risk.

Long COVID appears to be not one disease but different collections of symptoms all precipitated by an acute COVID infection, said Akiko Iwasaki, PhD, during the annual Robert J. Lefkowitz, MD, Distinguished Lecture.

Novel findings from a preclinical head-to-head comparison show that administering a COVID-19 vaccine as a nasal spray, rather than subcutaneous injection, enhances the body’s long-term immune memory, thereby increasing the vaccine’s overall effectiveness.

Probiotics, specifically lactobacillus, demonstrated significant ability to delay a COVID infection and reduce symptoms among a group of unvaccinated people who had been in contact with someone in their household diagnosed with COVID.

Mary Klotman, MD, Talks with Kanecia Zimmerman, MD, PhD, MPH, who is Duke's principal investigator for the Clinical Trials Data Coordinating Center for research on Long COVID.

A vaccine designed to protect against three different deadly coronaviruses shows success in mouse studies, demonstrating the viability of a pan-coronavirus vaccine developed by researchers at the Duke Human Vaccine Institute.

From Dominican and Puerto Rican to Mexican heritage, the choices made in confronting the virus are as diverse as the cultures represented in a new national study of COVID-19 patterns led by Duke University School of Medicine.